Objective: To provide an up to date comprehensive overview of the Afghanistan pharmaceutical sector situation and its future development needs and priorities.
Introduction

General background
The Islamic Republic of Afghanistan is a landlocked central Asian country consisting of 34 provinces and with a population of approximately 28 million. It is classified by the UN as a Least Developed Country (LDC), is in a state of ongoing conflict and can be described as both a fragile 1 and failed state 2 . The poor health, socioeconomic and governance status of Afghanistan is summarised by a number of indicators presented in Table 1 .
Pharmaceutical sector background
The first Afghanistan pharmaceutical sector assessment after the fall of the Taliban regime was conducted by the World Corruption perceptions index (rank out of 178) 3 
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Note: PPP = Purchasing Power Parity Pharmaceutical Affairs (GDPA), a directorate of the Ministry of Public Health (MoPH), which also oversees sector provincial management via a system of Provincial Pharmacy Officers (PPOs) located in Provincial Public Health Departments (PPHDs); and (ii) the International Donor Community (IDC), principally the World Bank, US Agency for International Development (USAID) and European Commission (EC), which finances and oversees the provision of medicines supplied via the Basic Package of Health Services (BPHS) by International Donor Community (IDC) contracted Non-Governmental Organisations (NGOs).
The corner stone of Afghanistan health and pharmaceutical sector development since 2003 has been the implementation of a BPHS 10 which includes a defined set of cost-effective interventions aimed at addressing the principal health problems of the population, with an emphasis on the most vulnerable groups, women and children, but with provisions made for the eventual incorporation of interventions targeting other vulnerable groups. More recently in 2005, the Essential Package of Hospital Services (EPHS) has been created in an attempt to develop a functional referral system for more severe cases of disease 11 .
Since 2002 there has been a significant increase in the quantity of both donated and privately imported medicines entering Afghanistan following the involvement of the international community in this country's health sector. The profile of the Afghanistan pharmaceutical market can only be described in general terms as there is a lack of accurate collected data 12 ; and where such data has been collected it is largely done on an ad hoc and non-repeated basis. For example, only one comprehensive baseline pharmaceutical sector indicator study, designed in accordance with WHO recommended
Afghanistan Stakeholders
International Donor Community (IDC) Stakeholders Other sector data and reports, where they exist, tend to be focused on specific sub sectors (particularly medicines procurement and distribution which is perhaps justifiable given the health sector priority of BPHS implementation) thus several sector knowledge gaps exist.
In this context, the objectives of this paper are to provide (i) a descriptive comprehensive overview of the pharmaceutical sector situation in Afghanistan, and identify (ii) future sector development needs and intervention priorities.
Methodology
The following methods were used to collect the data for this project. These methods are also discussed in a 2007-08 report by the author (JH) to the European Commission
12
. 
Structured interviews and workshop with Afghanistan pharmaceutical sector stakeholders
Sector data review
A thorough review, listed in Table 3 , of (a) all local available relevant health and pharmaceutical sector documents and reports (particularly from the MoPH and IDC), and (b) regional and international pharmaceutical sector reports and publications was conducted so as to inform the analysis and recommendations made by the EC Identification Mission.
Use of sector assessment tool methodology
Assessment was carried out based on available WHO sector assessment tools 13, 15 according to the scheme illustrated in Table 4 , and which is adapted by the authors from the WHO National Medicines Policy (NMP) scheme 16 which matches NMP components against the NMP objectives of medicines access, quality and rational use.
Apart from the above, in order to obtain a 'grass roots' feeling of the Afghanistan pharmaceutical sector situation, a number of facility visits were conducted to public and private health facilities, pharmacies, distributors, local pharmaceutical manufacturers, medical stores and medicines quality control facilities. Following the above steps, a full review and analysis of Afghanistan pharmaceutical sector policy and its implementation was conducted, covering sector administration, management, regulation, financing and pricing, supply system and market characteristics.
Results and discussion
A summary of key findings is presented in Table 5 in accordance with the sector overview scheme presented in the results and discussion section. Results are discussed under each sector area heading.
Medicines Supply and Market Profile
Afghanistan has a dual public and private sector medicines supply system. The public system concerns the provision (procurement, import, storage, distribution and dispensing) of the Basic and Essential Packages of Health Services by the Ministry of Public Health and the International Donor Community, principally the World Bank, USAID and EC who have divided geographic management responsibility of the 34 Afghan provinces between them and contracted national and international Non Governmental Organisations to implement medicines supply.
The number of participants in the private supply system is larger at every point in the supply chain compared to other economic sectors in Afghanistan. There is an oversupply of importers (~200 licensed), distributors (~ 200 known licensed and unlicensed) and pharmacies (~13,000 known licensed and unlicensed), as well as many grocery stores and street vendors • Pre-existing local production based severely damaged but beginning to re emerge
• Basis exists for production and export of herbal ingredients );
• Drugs are often sold as unpacked blisters (with no patient information leaflet), often they are expired;
• Prescription only medicines are sold without prescription and often directly to children;
• Rules on pharmacy physical conditions and coverage are frequently not observed (e.g. very often pharmacies are clustered together in central urban locations and there is a limited number of pharmacies in rural districts);
• Pharmacies frequently do not stock the full range of essential drugs;
• Pharmacy inspection is uncommon and haphazard and where it occurs it is conducted by a variety of inspectors from different authorities and not according to any particular inspection protocol);
• There is no evidence of any enforcement (no reported cases exist of pharmacies being closed for infringement of regulatory requirements). In the absence of accurate data, it estimated that (i) the private sector accounts for 70% of the total pharmaceutical market (of which 95% consists of imported medicines from many sources in the region), and (ii) 30% of the market consists of international drug donations which are provided largely through the BPHS/ EPHS essential medicines scheme, the balance provided through international humanitarian pharmaceutical assistance 12, 22 . Illegal imports, which can also contaminate the legitimate supply chain, probably account for greater than 50% of the total pharmaceutical market 12, 22 ; a major contributory factor that Afghanistan has lengthy porous borders, particularly the borders with Pakistan and Iran. The MoPH estimates that the number of unregistered far exceeds registered medicines on the market 12 .
Although identification of substandard and counterfeit medicines in the Afghanistan market is a straight forward task and cases can readily be identified 12 , for a number of reasons the estimation of the prevalence of substandard, counterfeit (falsified), adulterated and diverted medicines in Afghanistan is extremely difficult. Difficulties in estimating prevalence are due to weak Post Market Surveillance (PMS), a chaotic and complex supply chain and an absence of clear and internationally harmonised definitions of counterfeit and substandard medicines.
One recent study 23 was conducted in Afghanistan to examine medicines quality and which concluded that medicines provided publicly by the IDC through the BPHS were generally of an acceptable standard; however the sample size from the private sector was too small to draw any conclusions concerning private sector substandard medicine prevalence. Given the estimated high proportion of illegal imports a high prevalence of substandard (and counterfeit) medicines cannot be ruled out and PMS efforts need to be enhanced. The Afghan conflict situation is likely to provide fertile ground for pharmaceutical crime activity, particularly given the close association between organised crime and medicines counterfeiting 24 . Counterfeiting is also perhaps a disincentive for research-based and branded medicines manufacturers to register their products in Afghanistan.
In 2010, the WHO conducted a questionnaire-based survey of several EMRO i and SADC ii countries 25 , including Afghanistan, with the objective of reviewing the counterfeit medicine situation so as to provide a more informed basis for developing and implementing counterfeit medicine policy and action.
Conclusions applicable to most countries surveyed, including Afghanistan, were a need for (i) specific legislation that empowers National Medicines Regulatory Authorities (NMRAs) and criminalises medicines counterfeiting, (ii) strengthened cooperation and information-sharing among the various key players at national, regional and global levels, and (iii) strengthened weak market control systems. Thus, in order to tackle the problem in Afghanistan a number of actions are required, several of which will require IDC assistance for implementation.
Medicines Policy and Legislation
Afghanistan is in possession of a National Medicines Policy (NMP) dating from 2003 and which has been designed in accordance with the WHO national medicines policy model scheme and guidelines 16 . Aside from the creation of an Essential Medicines List (EML), last updated in 2007, and the supply of essential medicines via the BPHS/EPHS, other NMP provisions (e.g. rational medicines usage policies) are underrepresented in the MoPH pharmaceutical sector management programme, the latter effectively being the NMP implementation plan 26 . While medicines supply management is an important policy area and which hitherto has been seen as a priority area in view of the emphasis on BPHS implementation, other areas of NMP equally deserve and require attention for implementation.
The sector legislative and regulatory framework is provided by a framework Medicines Law (2006) and Regulations covering local manufacturing, import, procurement, distribution and retail. The Afghanistan Medicines Law omits several regulatory areas that would normally be included in a model national medicines law and includes a number of areas that normally would not be included 12 . For example, the law makes no provision for medicines intellectual property issues (IPR) issues, i.e. patent and brand name protection, data exclusivity and issues relating to Trade Related Intellectual Property Rights (TRIPS) flexibilities. Provisions for implementation and enforcement of the law and sanctions for violations are weak. There is scope to align the existing medicines legislation in accordance with regional and international standards and practices and to introduce stronger provisions concerning implementation, enforcement and sanctions.
Sector Administration and Management
Health sector stewardship is defined by the WHO as being one of the four essential functions of the health system in addition to service provision, resource generation and financing 27, 28 . The Ministry of Public Health General Directorate for Pharmaceutical Affairs is responsible for pharmaceutical sector stewardship (sector policy and regulation) but also, as a legacy of the Soviet occupation period, continues to perform a command style of sector management and consequently conducts a range of commercial activities outside of its stewardship role and not related to medicines policy and regulation such as manufacturing, operating a pharmacy retail chain, wholesaling, warehousing and importing. This situation is in conflict with market economy based systems being introduced by the IDC and has a detrimental impact on activities that are within its terms of reference.
The MoPH, and particularly its GDPA, is continuing to undergo a long period of restructuring with regular organisational changes often driven by political reasons and consequently remains unsettled and not modelled in conformance with the i East Mediterranean Regional Office of the WHO ii SADC -Southern African Development Community. Inter-governmental organisation of 15 southern African states Afghanistan is judged to be the second most corrupt country in the world 3 and evidence suggests that the Afghanistan health and pharmaceutical sector is particularly adversely affected by corruption 12, 22, 29 . Transparency International claims that in some countries up to two thirds of hospital medicines supplies are lost to corruption and fraud and it is estimated that 10-25% of global spending on public medicines procurement is lost to 
Afghanistan pharmaceutical sector development: problems and prospects
Other sector data, where it is available, tends to be collected on an ad hoc basis by the IDC and contracted NGOs, however many sector areas outside of medicines inventory management are not monitored or evaluated (e.g. medicines quality, safety, usage and pricing). The failure of sector data coordination occurs due to the fact that the sector is currently managed jointly by the Afghan authorities and several international donors. The actual assimilation and utilisation of available sector data by the MoPH GDPA is hard to determine. Thus, as is often the case in developing countries, local data is sparse and the majority of policy decisions tend to be based on data which is gathered, modelled and published by international agencies 31 .
There is much scope to adopt a unified, standardised and comprehensive pharmaceutical sector M&E system (which should be incorporated into the overall health sector M&E system) to serve the purposes of both the MoPH and the IDC. The introduction of regular pharmaceutical sector baseline studies can complement and feed into this system.
Medicines Regulation, Registration and Quality Control
The Afghanistan Licensed Drug List (LDL) 32 , is required to be submitted for all LDL applications. Thus there are no provisions for abbreviated medicines registration in the case of an existing reference product on the Afghanistan market. Limited provisions exist concerning intellectual property issues (i.e. data exclusivity, patent protection, registration of brand and trademark names).
The Ministry of Public Health Medicines Quality Control Laboratory (MQCL) is responsible for medicines Quality Control (QC) and carries out testing for registration, batch import QC, and ostensibly for Post Market Surveillance (PMS) purposes. As there is no capacity to conduct Good Manufacturing Practice (GMP) inspections and a lack of recognition of international manufacturing authorisations and GMP certificates, the MoPH relies on a system of testing every imported batch (except for batches imported by some international donors who have obtained a MoPH testing waiver), although the capacity and capability of the national Medicines QC laboratory to do such is far from adequate. The MQCL is not internationally accredited, is operating in a dilapidated condition, suffers from serious resource (staff and equipment) and operational deficiencies, and is inadequate in all respects to be able conduct medicines testing according to international standards 12 . The ultimate organisational position of the MQCL is yet to be determined.
Medicines import and export is regulated according to a batch import licensing system; however customs control procedures are reported by several stakeholders as being detrimental, inefficient and non transparent 12 . The rigid import license process and requirement for all batches to be QC tested by the central MQCL often results in delays of approximately three months for medicines to be imported into Afghanistan; often large amounts of import batch stock are damaged or misappropriated (diversion, 'system leakage') while in customs clearance; no customs risk analysis procedure is applied to imported medicines and there is no central customs bonded warehouse 22 . There is no system of medicines export and transit licensing. Importers are licensed by the MoPH and licenses can be obtained by general traders (i.e. not just specialist medicine distribution companies that employ a qualified person).
The Afghanistan medicines regulation system is underdeveloped, weakly implemented and not internationally harmonised. There are a number of weaknesses and gaps and principally there is a need to harmonise the medicines law and its regulations with existing international models, adopt internationally harmonised medicines registration procedures, invest in an adequate medicines QC infrastructure and implement a pharmacovigilance system.
Medicines Financing, Reimbursement and Pricing
It is difficult to make an accurate assessment of the public medicines financing situation in Afghanistan for a number of reasons: (i) no national health account system exists, (ii) there is no central compilation of medicines financing statistics or national medicines budget formula in operation, (iii) public health financing is derived and applied by a number of funders, i.e. Ministry of Public Health and International Donor Community, and (iv) medicines financing data is not routinely collected and where it exists it is of a limited nature. Thus there is a need for the IDC to assist and involve the MoPH in assessing medicines needs and monitoring sector financial flows.
The public Basic and Essential Packages of Health Services medicines budget is ~ 4 USD per capita per year 12 . The best available statistics suggest that 70% of the country's medicines needs are provided via the private sector with the remainder being supplied by the 100% publicly funded essential medicine BPHS/EPHS scheme (90% funded by IDC with the Afghanistan Ministry of Finance contributing the balance); however the proportion of essential medicines provided by the public BPHS/EPHS scheme which is estimated to have 80% population coverage (as a % of total essential drugs supplied) is proportionately higher. It is estimated that an average of 20% of the BPHS/EPHS budget across all donors is spent on medicines 12 , although there is a wide variation in per capita medicines expenditure between provinces and between donors (as a result of variations in medicines financing policies between the donors and which are not centrally coordinated).
Large variations occur in medicines availability and per capita BPHS medicines expenditure between the provinces for reasons that are not entirely clear and may be partly related to donor and MoPH incoordination in terms of estimating medicines needs. In spite of the public BPHS/EPHS system 'out of pocket' payments Afghanistan pharmaceutical sector development: problems and prospects for medicines constitute a significant part of private household expenditure 34 . Anecdotal evidence suggests that patients meet a substantial part of their medicines needs from the private sector for a number of reasons; e.g. perception of product quality source, lack of availability in public health facilities, long waiting times, ability to obtain medicines without the need for a prescription. Thus fundamental medicines availability issues in Afghanistan require major attention.
Afghanistan Medicines legislation makes provision for controlling medicines prices via defining import, wholesale and retail margins, for both publicly and privately supplied medicines. Despite the existence of legislation governing medicines price margins, observance of regulated margins is not followed in practice and are hardly inspected or enforced. Very often pharmacies set retail prices by referring to the retail price of medicines in either Pakistan or Iran. The BPHS/EPHS medicines list is based on the MoPH EDL and inclusion of a medicine on the list requires the submission of pharmacoeconomic data 35 , however the appropriateness and capacity of the Afghanistan authorities to employ pharmacoeconomic analysis in medicines assessment has to be seriously questioned. Strong arguments exist against blindly applying developed country pharmacoeconomic models and techniques in LDCs as they can in the first instance effectively manage scarce resources by applying effective pricing policies, differential pricing and by improving transparency and accountability within the medicines system 36 .
It is unrealistic in the long term to expect the IDC to continue to fund Afghanistan's essential medicines needs so a system needs to be put in place whereby all regulatory-approved essential medicines, irrespective of source, come under the provisions of a national medicines financing and reimbursement system and with the introduction of international reference prices.
Rational Medicines Usage (RMU)
Irrational medicines prescribing, dispensing and consumption have been reported as being widespread in Afghanistan and include overuse of antimicrobials and injections and the dispensation of half treatment courses 9, 14 . Medicines are widely available without prescription and a serious problem exists with diagnosis and prescription by unqualified persons posing as doctors in private clinics and working in private pharmacies as well as by street vendors 22 . It has been noted that consumers cannot always afford complete courses of therapy and that generic medicines are perceived to be of low quality leading to the prescription of high doses and multiple products in the same therapeutic category 9 . The usage of traditional and herbal medicines in Afghanistan medical practice continues to be a major part of health care delivery although utilised traditional remedies may or may not be clinically appropriate 22 .
The availability of objective medicines information is particularly weak although a few public education campaigns on medicines usage are in existence 22 . The Afghanistan National Medicines Policy makes provision for implementing several RMU policy measures, e.g. creation of impartial medicines information resources (such as a national medicines information centre and a national medicines formulary) and national clinical protocols, but aside from the creation of the EML so far none have been implemented due to capacity and resource constraints.There is a real need for the implementation of a range of RMU policy measures including professional curricula development, medicines utilisation review and household consumption studies, health facility Drugs and Therapeutics Committees (DTCs), objective medicines information (for prescribers, dispensers and consumers), clinical protocols, and Good Pharmacy Practice guidelines.
Local Pharmaceutical Industry Development and Trade Policy
Only a decade ago Afghanistan was producing the majority of its medicine needs inside the country and was even developing an export market. As a result of the many recent conflicts in is history, Afghanistan's pharmaceutical industry, which was strong in the period between the 1970s to the early 1990s, has been severely damaged. There are currently two credible foreignowned manufacturers and a pre-existing major state-owned manufacturer (the latter existing in a dilapidated condition but attempting to revitalise its production base in accordance with international manufacturing standards). In addition there are a large number of small scale 100 percent Afghan-owned pharmaceutical manufacturers, the number of which is growing.
Afghanistan also produces many herbal ingredients that are exported for use in herbal medicines; 28.6 million US$ of 'medical plants' were exported in 2010 accounting for 7% of total exports 37 . Thus the development of herbal medicine local production appears rational as the country is a reservoir of potentially valuable herbal active substances with cultivation experience.
The MoPH considers the development of local production and import substitution to be a major pharmaceutical sector strategic objective, but no state incentive schemes exist for supporting local essential medicines production. Due to its landlocked location the costs of importing bulky essential drugs can be prohibitive and above international reference prices and its porous borders make it difficult to control imports. Thus there is real justification for developing a local pharmaceutical industry that can contribute to supplying the country's essential medicines needs and which will require introducing effective import substitution policy measures.
Conclusions
The Afghanistan pharmaceutical sector for several reasons is one of the least developed in the world, operates in a chaotic faction and suffers from many weaknesses that cover the entire spectrum of sector activities. The market presence of substandard and counterfeit medicines is likely to be significant and should be considered a public health menace demanding
